Background Adjuvant and neoadjuvant breast cancer treatments can reduce breast cancer
mortality but may increase mortality from other causes. Information regarding treatment …

Despite the exceptional progress in breast cancer pathogenesis, prognosis, diagnosis, and
treatment strategies, it remains a prominent cause of female mortality worldwide …

PURPOSE To develop guideline recommendations concerning optimal neoadjuvant therapy
for breast cancer. METHODS ASCO convened an Expert Panel to conduct a systematic …

The last 25 years have seen significant growth in new therapeutic options for breast cancer,
termed targeted therapies based on their ability to block specific pathways known to drive …

Simple Summary Breast cancer can express, at varied levels, a protein named HER2,
commonly responsible for making it grow and send distant metastases. In the past, patients …

The prognosis of patients with early stage breast cancer has greatly improved in the past
three decades. Following the first adjuvant endocrine therapy and chemotherapy trials …

Background A subcutaneous formulation of pertuzumab and trastuzumab with recombinant
human hyaluronidase in one ready-to-use, fixed-dose combination vial (pertuzumab …

Abstract This Review Article provides a multi-stakeholder view on the current status of
neoadjuvant therapy in lung cancer. Given the success of oncogene-targeted therapy and …

PURPOSE The aim of this work is to update key recommendations of the ASCO guideline
adaptation of the Cancer Care Ontario guideline on the selection of optimal adjuvant …

Background We determined the prognostic impact of lymphovascular invasion (LVI) in a
large, national, multicenter, retrospective cohort of patients with early breast cancer (BC) …